|
 |
Obesity / Weight Loss
2010 –PI - Ronald Brazg, MD (Phase 2b)
A Double Blind, Multi-Center, Randomized, Parallel-Group, Study to Assess the Efficacy and Safety 400 mg of An Investigational Medication and 120 mg of Orlistat Administered Individually or Combined Orally Three Times Per Day with a Reduced Calorie Diet (RCD) in Obese Subjects.
2009 –PI – Allen Sussman, MD (Phase 3a) – Study Awarded
Effect of An Investigational Medication on Body Weight in Non-Diabetic Obese Subjects or Overweight Subjects With Comorbidities: A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicentre, Multinational Trial with Stratification of Subject to Either One or Three Years of Treatment Based on Pre-Diabetes Status at Randomization.
2008 PI – Leslie Klaff, MD, Ph D (Phase 2)
The Effect of Dose Titration of an Investigational Medication in Overweight and Obese Patients with Type 2 Diabetes Mellitus
2008 PI - Ronald Brazg, MD (Phase 2)
A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Efficacy and Safety Trial to Evaluate the Effect of an investigational medication on Weight in Obese and Overweight Subjects
2007 PI - Allen Sussman, MD (Phase 3)
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Determine the Safety and Efficacy of An Investigational Medication in the Treatment of Obesity in An Adult Population with BMI>35
2007 PI - Allen Sussman, MD (Phase 3)
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Determine the Safety and Efficacy of An Investigational Medication in the Treatment of Obesity in Adults with Obesity-Related Co-Morbid Conditions
2007 PI - Ronald Brazg, MD (Phase 3)
A Double-Blind, Multi-Center, Randomized, Parallel-Group, Yearlong Study to Asssess the Efficacy and Safety of An Investigational Medication Administered Orally Once Daily with A Reduced Calorie Diet in Obese Males and Females.
2006- PI Ronald Brazg, MD
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter study Evaluating the Efficacy and Safety of Three Doses of An Investigational Medication in Abdominally Obese Patients with Atherogenic Dylsipidemia.
2006 - PI Leslie Klaff, MD, Ph.D (Phase III)
A 2-Year, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of An Investigational Medication in the Treatment of Obese Subjects.
2006 - PI Leslie Klaff, MD, Ph.D (Phase III)
A 1-Year, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of An Investigational Medication in the Treatment of Overweight, Oral Agent-Treated Subjects with Type 2 Diabetes Mellitus.
2006 - PI Ronald Brazg, MD (Phase 2)
Study to Assess the Efficacy and Tolerability of An Investigational Medication in Maintaining Weight Loss Induced by Diet in Obese Patients
2006 - PI Leslie Klaff, MD, Ph.D. (Phase IV)
Effect on Weight Loss of An Approved Medication vs. Placebo in Subjects with Type 2 Diabetes Participating in a Lifestyle Modification Program.
2006 - PI Ronald Brazg, MD (Phase IIa)
A Study to Assess the Safety, Tolerability, and Efficacy of An Investigational Medication in Obese Patients
2005- (Phase III) PI Ronald Brazg, MD
Randomized, multicenter, double-blind, placebo-controlled, two-arm parallel group trail of rimonabant 20-mg od, for inhibitor of atherosclerosis progression assessed by carotid artery intima-media thickness (CIMT), in overweight patients with additional risk factors.
2005 PI Ronald Brazg, MD (Phase II)
A Double-Blind, Multicenter Randomized Parallel Group, 16-Week Study of An Investigational Medication Administered Orally Once A Day With or Without a Low Calorie Diet Lead In Obese Males and Females
2005 PI Leslie Klaff, MD,Ph.D (Phase IIa)
A Dose Titration Study to Assess the Efficacy, Safety and Tolerability of An Investigational Medication in Obese Patients
2005 PI Allen Sussman, MD (Phase III)
A Two-Year Study (One Year Weight Loss followed by One Year Prevention of Weight Regain) to Assess the Safety, Tolerability and Efficacy of An Investigational Medication in Obese Patients
2005 PI Ronald Brazg, MD (Phase Ib)
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of An Investigational Nasal Spray in Obese Patients
2004 PI Ronald Brazg, MD (Phase IIa)
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of an investigational medication in Obese Patients
2004 PI Ronald Brazg, MD (Phase IIa)
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Assess the Efficacy and Safety of an investigational medication in the Treatment of Obese, Type 2 Diabetic Subjects Managed with Diet or Metformin.
2003 PI Ronald Brazg, MD (Phase III)
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of an investigational medication in Maintaining Weight Loss Induced by a Very Low Calorie Diet in Obese Patients
2003 Ronald Brazg, MD (Phase III)
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of an investigational medication in Obese Patients
2002 PI Ronald Brazg, MD (Phase IIa)
A dose range-finding, double-blind, randomized, placebo-controlled, multicenter study to assess the safety, tolerability, and efficacy of an investigational medication in obese subjects.
2001 PI - Allen Sussman, MD
A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter study of weight-reducing and prevention of weight regain effects and safety of an investigational drug in obese patients with or without comorbidities.
2001 PI - Ronald Brazg, MD
A Phase III, 12-month, double blind, randomized, parallel group, placebo controlled, efficacy and safety study of an investigational medication in overweight and obese subjects with a 12-month open-label extension phase.
2001 PI - Ronald Brazg, MD
A Phase III, Multicenter, Two-Arm Study to Assess the Efficacy and Safety of An Investigational Oral Medication in the Treatment of Obesity in Subjects With Hypertension and/or Dyslipidemia
2001 PI - Allen Sussman, MD
An Investigational Medication Dose-Response, Efficacy, and Safety: A 12-Week Randomized, Multicenter, Double-Blind, Double-Dummy, Parallel-Group Study of Metformin and Five Doses of an Investigational Medication in Previously Treated OHA Monotherapy Obese Subjects With Type 2 Diabetes
1999 PI - Ronald Brazg, MD
A Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Four Doses of an Investigational Medication in Obese Patients
1999 PI - Allen M. Sussman, MD
A Randomized, Placebo-Controlled, Double-blind Study to Evaluate the Safety and Efficacy of Subcutaneously Administered A-300 in Obese Subjects.
1996 PI - Ronald Brazg, MD
A Fifty-Two Week, Multicenter, Double-blind, Placebo-Controlled, Parallel-Group Study to Compare the Effects of an Investigational Medication With Those of Placebo in Mild to Moderate Obese Patients Whose Hypertension is Controlled by a Calcium-Channel Blocker, With or Without Concomitant Thiazide Diuretic Therapy.
1992-1993 PI - Allen Sussman, MD
Evaluation of an investigational medication Versus Placebo for Gallstone Prophylaxis During Very Low Calorie Diet-Induced Rapid Weight Loss |
Phase I & Pharmacokinetic Unit